Pfizer Inc

Pfizer shares surge after analyst upgrade and promising phase‑II breast‑cancer data for PF‑Lym‑210, highlighting strong pipeline and solid earnings growth.

Pfizer’s latest atirmociclib phase‑two results spark optimism while its ambitious 20‑trial pipeline and strong cash flow shape long‑term strategy, revealing key risks and investment insights.

FTC eyes drug makers as key patents expire, aiming to cut price spikes and speed generic entry while protecting innovation.

Pfizer CEO Albert Bourla boosts his stake by converting phantom stock units into shares, showing how pharma leaders align incentives with shareholder value.

Pfizer’s shift from COVID to a diversified pipeline—trispecific AD drug, GLP‑1 weight loss in China, and oncology Phase‑3 wins—offers high‑margin growth, but carries regulatory and competitive risks.

Pfizer’s $29 M SEC settlement, steady dividends, and bold oncology and GLP‑1 pipeline moves show how the pharma giant balances compliance, investor returns, and long‑term growth.

Pfizer’s new FDA approvals for BRAFTOVI and PADCEV/Keytruda promise $2.7 billion+ in 5‑year revenue, but patent risk, high‑cost logistics and payer value contracts require smart pricing, supply‑chain resilience and data‑driven care platforms to secu…

Pfizer’s Braftovi phase‑three success shows a 30 % PFS boost for metastatic colorectal cancer, but high monthly costs and reimbursement hurdles mean strategic pricing and supply‑chain upgrades will be critical to unlocking its $120 m+ market potenti…

Pfizer’s new license with Novavax’s Matrix‑M adjuvant and sale of its ViiV stake signal a sharpened focus on high‑margin vaccine and biotech opportunities, boosting R&D speed and future profitability.

Pfizer’s breakthrough BRAF‑targeted colorectal cancer results and new obesity drug plans highlight its dual strategy to dominate oncology while opening a high‑margin consumer market, boosting investor confidence.